Please Scroll Down to See Forums Below Shoot Me Up
New member
just curious to anyguys that ever heard of Cynoplus and just wanted to make sure it was T3? for those that have used it, did you find it affective?
.jpg "Research Chemical Sciences")
.png "Research Chemical Sciences")
just baught cynoplus in mexico today, is this T3>?
- Thread starter Shoot Me Up
- Start date
Shoot Me Up
New member
please help me guys, i am sketchy about this product
Shoot Me Up
New member
asdf
HellaRipped
New member
you mean mcg right?
HellaRipped
New member
Here ya go, i found this article.....
CYNOPLUS
Cynoplus*
Tabletas
(Liotironina and sódica levotiroxina)
IT FORMS PHARMACEUTICS And FORMULATION:
Each tablet contains:
Sódica, equivalent Liotironina a 30 mcg
of liotironina
Levotiroxina sódica 120 mcg
Excipiente, c.b.p. 1 tablet.
THERAPEUTIC INDICATIONS: Cynoplus * is indicated in the treatment of the hipotiroidismo when it exists a diminution or absence of tiroidea function caused by antitiroideos agents, x-ray, primary atrophy, partial or total extraction of the gland or by functional alterations of the same one. Cynoplus * is effective in the treatment of the hipotiroidismo of any etiología. The use of Cynoplus * as substitute therapy in the simple goiter (nontoxic) produces like result a fast reduction in the size of the gland thyroid.
Cynoplus * has demonstrated to be of utility in the therapy of maintenance of the hipotiroidismo.
FARMACOCINÉTICA And FARMACODINAMIA:
Cynoplus * contains L-triyodotironina or liotironina (T 3 ) and L-tetrayodotironina or levotiroxina (T 4 ), synthetic forms of human tiroideas hormones, in a proportion balanced in weight from 1 to 4 respectively and in which each hormone approximately offers half of the total of therapeutic activity. The proportion of active hormones that appear in Cynoplus * reproduces the clinical and biochemical effects of the dried thyroid and the endogenous secretion of the thyroid. Cynoplus * is prepared with standardized synthetic hormones, reason why its constant composition is safe.
95% of the liotironina are absorbed in tracto gastrointestinal and reach weaves easily. The levotiroxina has an absorption in tracto gastrointestinal that varies from the 50 to 80%. The maximum effect of the liotironina is apparent between 24 and 72 hours after its ingestion and lasts by more than 72 hours. The levotiroxina reaches its complete effect between 1 and 3 weeks, and the effect lasts by a similar lapse after suspending its administration. The life average plasmática of liotironina and levotiroxina is 1-2 days and 6-7 days, respectively.
The levotiroxina is united more strongly to plasmáticas proteins that the liotironina, reason why has a slower beginning of prolonged action more and than the liotironina.
Peripheral weaves the levotiroxina is turned to triyodotironina, situation that is diminished when the hormones are associates in the same formulation, reason why the present hormones in Cynoplus *, complement their effects.
CONTRAINDICATIONS: Tirotoxicosis, unstable angor, acute infarct of the myocardium. Cynoplus * is contraindicated in patients with irreversible adrenal insufficiency since it increases the demand of adrenocorticales hormones and can cause an acute adrenal crisis.
RESTRICTIONS OF USE DURING The PREGNANCY And The LACTANCIA: The tiroideas hormones do not cross the placentaria barrier quickly. The clinical experience indicates that Cynoplus * lacks adverse effects on the fetus when is administered during the pregnancy.
With base in these knowledge, the substitute tiroideo treatment to hipotiroideas women will not have to be discontinued during the pregnancy. The tiroideas hormones are excreted in minimum amounts in maternal milk and its use has not been associated to serious adverse reactions; nevertheless, precaution must be had when tiroideas hormones to women are administered during the lactancia.
SECONDARY And ADVERSE REACTIONS: The overdoses of tiroideas hormones can give rise to the appearance of signs and symptoms of hipertiroidismo: excitabilidad, loss of weight, palpitaciones, arrhythmias, tachycardia, diarrea, perspiration, tremor, migraine and intolerancia to the heat.
The effects do not appear immediately and the symptoms can appear of 1 to 2 weeks after the initial dose. The medication in these cases will have to be interrupted until the disappearance of the symptoms, to reiniciar it one or two later days with smaller doses.
INTERACTIONS MEDICAMENTOSAS And OF ANOTHER SORT: The administration of Cynoplus * can generate farmacológicas interactions with diverse fármacos.
It increases the anticoagulating effects of the warfarina and acenocumarol. It can cause an increase in the insulin requirements or oral hipoglucemiantes in diabetic patients. The colestiramina makes difficult the tiroideas hormone absorption.
The oral estrogen use or contraceptives with estrogens, can diminish the free levotiroxina and for that reason increase the requirements of tiroidea hormone. Tiroideas hormone use the tricyclic along with imipramina and other antidepressants, can increase the antidepressing activity, as well as the activity of tiroideas hormones. The tiroideas hormones can harness the poisonous effects of the digitalis; also, the therapy of tiroidea substitution increases the rate metabolic, which can require an increase in the dose of the digitalis. It has been reported that the concomitante administration of tiroideas hormones and ketamina, can produce hypertension and tachycardia. The tiroideas hormones increase to the adrenérgico effect of catecholamines like epinefrina and norepinefrina.
ALTERATIONS IN THE RESULTS OF LABORATORY TESTS: They have not been reported with the present association in Cynoplus *. When the clinical evidences and of laboratory show hipotiroidismo and an suitable dose is being administered, means that the patient does not follow the instructions, a poor absorption or an excessive fecal loss. The intracellular resistance to the medicine is very rare.
PRECAUTIONS IN RELATION TO EFFECTS OF CARCINOGÉNESIS, MUTAGÉNESIS, TERATOGÉNESIS And ON The FERTILITY: Cynoplus * will have to be administered with precaution in patients with cardiovascular diseases, including arterial hypertension. Any cardiovascular complication will require a reduction in the dose. It must be had special well-taken care of in patients with diseases of the coronary arteries, since the possibility of arrhythmias cardiac can be greater in patients dealt with tiroideas hormones.
In patients in those who the hipotiroidismo is secondary to hipopituitarismo, it is probable that adrenal insufficiency coexists. When this happens, this last one will have to be corrected by means of corticosteroides before the tiroideas hormone administration.
Studies have not been made in long term animals to evaluate the carcinogénico, mutagénico, teratogénico potential or effects on the fertility.
DOSE And VIA OF ADMINISTRATION: Oral.
Cynoplus * is administered generally in a single taking, of preference before the breakfast.
It is recommended to initiate daily with average tablet of Cynoplus * during 1 to 2 weeks. Later, it will be able to be increased daily to a tablet during 1 to 2 weeks more. In agreement with the clinical answer and the data of laboratory, the dose will be able to be increased or to diminish itself, remembering that necessary the final dose, varies individually of patient to patient. In children, it will have to be increased to the dose every 2 weeks. In old patients, Cynoplus * must be administered with precaution since the hidden presence of cardiovascular diseases is common. In these cases the treatment with low doses must begin and if symptoms appear or the existing ones worsen, the dose must be diminished.
MANIFESTATIONS And HANDLING OF SOBREDOSIFICACIÓN Or ACCIDENTAL INGESTION: In case of sobremetering, symptoms like headache, irritability, nervousness, excessive perspiration, tachycardia, increase of the intestinal motilidad can appear. The cases of chest angina or congestiva insufficiency can be aggravated cardiac, and can be developed a shock picture.
The excessive sobremetering can present/display symptoms that make think about a tiroidea crisis, and will produce manifestations of hipertiroidismo. In anyone of these cases the treatment by several days and begin again it but with a smaller dose must be suspended.
If the sobremetering is acute, must be avoided the absorption of the medicine with the induction of the vomit and gastric washing. The treatment in cases of shock consists of support measures and must consider the treatment for not recognized adrenal insufficiency. In order to treat the increased likeable activity, antiadrenérgicos medicines like propranolol can be included.
PRESENTATION: Bottle with 50 tablets.
RECOMMENDATIONS ON STORAGE: Consérvese in fresh and dry place.
PROTECTION LEGEND:
Its sale requires medical prescription. It is not left the reach
of the children. Exclusive Literature for doctors.
Grossman Laboratories, S. A.
Reg. Núm. 81906, S. S. A.
Lear-303921/rm99
CYNOPLUS
Cynoplus*
Tabletas
(Liotironina and sódica levotiroxina)
IT FORMS PHARMACEUTICS And FORMULATION:
Each tablet contains:
Sódica, equivalent Liotironina a 30 mcg
of liotironina
Levotiroxina sódica 120 mcg
Excipiente, c.b.p. 1 tablet.
THERAPEUTIC INDICATIONS: Cynoplus * is indicated in the treatment of the hipotiroidismo when it exists a diminution or absence of tiroidea function caused by antitiroideos agents, x-ray, primary atrophy, partial or total extraction of the gland or by functional alterations of the same one. Cynoplus * is effective in the treatment of the hipotiroidismo of any etiología. The use of Cynoplus * as substitute therapy in the simple goiter (nontoxic) produces like result a fast reduction in the size of the gland thyroid.
Cynoplus * has demonstrated to be of utility in the therapy of maintenance of the hipotiroidismo.
FARMACOCINÉTICA And FARMACODINAMIA:
Cynoplus * contains L-triyodotironina or liotironina (T 3 ) and L-tetrayodotironina or levotiroxina (T 4 ), synthetic forms of human tiroideas hormones, in a proportion balanced in weight from 1 to 4 respectively and in which each hormone approximately offers half of the total of therapeutic activity. The proportion of active hormones that appear in Cynoplus * reproduces the clinical and biochemical effects of the dried thyroid and the endogenous secretion of the thyroid. Cynoplus * is prepared with standardized synthetic hormones, reason why its constant composition is safe.
95% of the liotironina are absorbed in tracto gastrointestinal and reach weaves easily. The levotiroxina has an absorption in tracto gastrointestinal that varies from the 50 to 80%. The maximum effect of the liotironina is apparent between 24 and 72 hours after its ingestion and lasts by more than 72 hours. The levotiroxina reaches its complete effect between 1 and 3 weeks, and the effect lasts by a similar lapse after suspending its administration. The life average plasmática of liotironina and levotiroxina is 1-2 days and 6-7 days, respectively.
The levotiroxina is united more strongly to plasmáticas proteins that the liotironina, reason why has a slower beginning of prolonged action more and than the liotironina.
Peripheral weaves the levotiroxina is turned to triyodotironina, situation that is diminished when the hormones are associates in the same formulation, reason why the present hormones in Cynoplus *, complement their effects.
CONTRAINDICATIONS: Tirotoxicosis, unstable angor, acute infarct of the myocardium. Cynoplus * is contraindicated in patients with irreversible adrenal insufficiency since it increases the demand of adrenocorticales hormones and can cause an acute adrenal crisis.
RESTRICTIONS OF USE DURING The PREGNANCY And The LACTANCIA: The tiroideas hormones do not cross the placentaria barrier quickly. The clinical experience indicates that Cynoplus * lacks adverse effects on the fetus when is administered during the pregnancy.
With base in these knowledge, the substitute tiroideo treatment to hipotiroideas women will not have to be discontinued during the pregnancy. The tiroideas hormones are excreted in minimum amounts in maternal milk and its use has not been associated to serious adverse reactions; nevertheless, precaution must be had when tiroideas hormones to women are administered during the lactancia.
SECONDARY And ADVERSE REACTIONS: The overdoses of tiroideas hormones can give rise to the appearance of signs and symptoms of hipertiroidismo: excitabilidad, loss of weight, palpitaciones, arrhythmias, tachycardia, diarrea, perspiration, tremor, migraine and intolerancia to the heat.
The effects do not appear immediately and the symptoms can appear of 1 to 2 weeks after the initial dose. The medication in these cases will have to be interrupted until the disappearance of the symptoms, to reiniciar it one or two later days with smaller doses.
INTERACTIONS MEDICAMENTOSAS And OF ANOTHER SORT: The administration of Cynoplus * can generate farmacológicas interactions with diverse fármacos.
It increases the anticoagulating effects of the warfarina and acenocumarol. It can cause an increase in the insulin requirements or oral hipoglucemiantes in diabetic patients. The colestiramina makes difficult the tiroideas hormone absorption.
The oral estrogen use or contraceptives with estrogens, can diminish the free levotiroxina and for that reason increase the requirements of tiroidea hormone. Tiroideas hormone use the tricyclic along with imipramina and other antidepressants, can increase the antidepressing activity, as well as the activity of tiroideas hormones. The tiroideas hormones can harness the poisonous effects of the digitalis; also, the therapy of tiroidea substitution increases the rate metabolic, which can require an increase in the dose of the digitalis. It has been reported that the concomitante administration of tiroideas hormones and ketamina, can produce hypertension and tachycardia. The tiroideas hormones increase to the adrenérgico effect of catecholamines like epinefrina and norepinefrina.
ALTERATIONS IN THE RESULTS OF LABORATORY TESTS: They have not been reported with the present association in Cynoplus *. When the clinical evidences and of laboratory show hipotiroidismo and an suitable dose is being administered, means that the patient does not follow the instructions, a poor absorption or an excessive fecal loss. The intracellular resistance to the medicine is very rare.
PRECAUTIONS IN RELATION TO EFFECTS OF CARCINOGÉNESIS, MUTAGÉNESIS, TERATOGÉNESIS And ON The FERTILITY: Cynoplus * will have to be administered with precaution in patients with cardiovascular diseases, including arterial hypertension. Any cardiovascular complication will require a reduction in the dose. It must be had special well-taken care of in patients with diseases of the coronary arteries, since the possibility of arrhythmias cardiac can be greater in patients dealt with tiroideas hormones.
In patients in those who the hipotiroidismo is secondary to hipopituitarismo, it is probable that adrenal insufficiency coexists. When this happens, this last one will have to be corrected by means of corticosteroides before the tiroideas hormone administration.
Studies have not been made in long term animals to evaluate the carcinogénico, mutagénico, teratogénico potential or effects on the fertility.
DOSE And VIA OF ADMINISTRATION: Oral.
Cynoplus * is administered generally in a single taking, of preference before the breakfast.
It is recommended to initiate daily with average tablet of Cynoplus * during 1 to 2 weeks. Later, it will be able to be increased daily to a tablet during 1 to 2 weeks more. In agreement with the clinical answer and the data of laboratory, the dose will be able to be increased or to diminish itself, remembering that necessary the final dose, varies individually of patient to patient. In children, it will have to be increased to the dose every 2 weeks. In old patients, Cynoplus * must be administered with precaution since the hidden presence of cardiovascular diseases is common. In these cases the treatment with low doses must begin and if symptoms appear or the existing ones worsen, the dose must be diminished.
MANIFESTATIONS And HANDLING OF SOBREDOSIFICACIÓN Or ACCIDENTAL INGESTION: In case of sobremetering, symptoms like headache, irritability, nervousness, excessive perspiration, tachycardia, increase of the intestinal motilidad can appear. The cases of chest angina or congestiva insufficiency can be aggravated cardiac, and can be developed a shock picture.
The excessive sobremetering can present/display symptoms that make think about a tiroidea crisis, and will produce manifestations of hipertiroidismo. In anyone of these cases the treatment by several days and begin again it but with a smaller dose must be suspended.
If the sobremetering is acute, must be avoided the absorption of the medicine with the induction of the vomit and gastric washing. The treatment in cases of shock consists of support measures and must consider the treatment for not recognized adrenal insufficiency. In order to treat the increased likeable activity, antiadrenérgicos medicines like propranolol can be included.
PRESENTATION: Bottle with 50 tablets.
RECOMMENDATIONS ON STORAGE: Consérvese in fresh and dry place.
PROTECTION LEGEND:
Its sale requires medical prescription. It is not left the reach
of the children. Exclusive Literature for doctors.
Grossman Laboratories, S. A.
Reg. Núm. 81906, S. S. A.
Lear-303921/rm99
Similar threads
